Product Code: TMRGL84872
The report provides revenue of the global glioma treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global glioma treatment market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the glioma treatment market.
The report delves into the competitive landscape of the global glioma treatment market. Key players operating in the global glioma treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global glioma treatment market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Glioma Treatment Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Glioma Treatment Market Analysis and Forecasts, 2017-2031
5. Key Insights
- 5.1. Key Industry Events (Mergers & Acquisitions, Product Launches, Partnerships)
- 5.2. Pipeline Analysis
- 5.3. Low Grade Glioma: Overview
- 5.4. Disease Prevalence Rate & Incidence Rate Globally
- 5.5. Covid-19 Pandemic Impact on the Industry
6. Global Glioma Treatment Market Analysis and Forecast, by Type
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Type, 2017-2031
- 6.3.1. Low-Grade
- 6.3.1.1. grade I
- 6.3.1.2. grade II
- 6.3.2. High-grade
- 6.3.2.1. grade III
- 6.3.2.2. grade IV
- 6.4. Market Attractiveness, by Type
7. Global Glioma Treatment Market Analysis and Forecast, by Treatment
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Treatment, 2017-2031
- 7.3.1. Surgery
- 7.3.2. Radiation Therapy
- 7.3.3. Chemotherapy
- 7.3.4. Targeted Drug Therapy
- 7.3.5. Others
- 7.4. Market Attractiveness, by Treatment
8. Global Glioma Treatment Market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Market Value Forecast, by Region
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Market Attractiveness, by Region
9. North America Glioma Treatment Market Analysis and Forecast
- 9.1. Introduction
- 9.2. Market Value Forecast, by Type, 2017-2031
- 9.2.1. Low-Grade
- 9.2.1.1. grade I
- 9.2.1.2. grade II
- 9.2.2. High-grade
- 9.2.2.1. grade III
- 9.2.2.2. grade IV
- 9.3. Market Value Forecast, by Treatment, 2017-2031
- 9.3.1. Surgery
- 9.3.2. Radiation Therapy
- 9.3.3. Chemotherapy
- 9.3.4. Targeted Drug Therapy
- 9.3.5. Others
- 9.4. Market Value Forecast, by Country, 2017-2031
- 9.4.1. U.S.
- 9.4.2. Canada
- 9.5. Market Attractiveness Analysis
- 9.5.1. By Type
- 9.5.2. By Treatment
- 9.5.3. By Country
10. Europe Glioma Treatment Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Market Value Forecast, by Type, 2017-2031
- 10.2.1. Low-Grade
- 10.2.1.1. grade I
- 10.2.1.2. grade II
- 10.2.2. High-grade
- 10.2.2.1. grade III
- 10.2.2.2. grade IV
- 10.3. Market Value Forecast, by Treatment, 2017-2031
- 10.3.1. Surgery
- 10.3.2. Radiation Therapy
- 10.3.3. Chemotherapy
- 10.3.4. Targeted Drug Therapy
- 10.3.5. Others
- 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 10.4.1. Germany
- 10.4.2. U.K.
- 10.4.3. France
- 10.4.4. Italy
- 10.4.5. Spain
- 10.4.6. Rest of Europe
- 10.5. Market Attractiveness Analysis
- 10.5.1. By Type
- 10.5.2. By Treatment
- 10.5.3. By Country/Sub-region
11. Asia Pacific Glioma Treatment Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Type, 2017-2031
- 11.2.1. Low-Grade
- 11.2.1.1. grade I
- 11.2.1.2. grade II
- 11.2.2. High-grade
- 11.2.2.1. grade III
- 11.2.2.2. grade IV
- 11.3. Market Value Forecast, by Treatment, 2017-2031
- 11.3.1. Surgery
- 11.3.2. Radiation Therapy
- 11.3.3. Chemotherapy
- 11.3.4. Targeted Drug Therapy
- 11.3.5. Others
- 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.4.1. China
- 11.4.2. Japan
- 11.4.3. India
- 11.4.4. Australia & New Zealand
- 11.4.5. Rest of Asia Pacific
- 11.5. Market Attractiveness Analysis
- 11.5.1. By Type
- 11.5.2. By Treatment
- 11.5.3. By Country/Sub-region
12. Latin America Glioma Treatment Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Type, 2017-2031
- 12.2.1. Low-Grade
- 12.2.1.1. grade I
- 12.2.1.2. grade II
- 12.2.2. High-grade
- 12.2.2.1. grade III
- 12.2.2.2. grade IV
- 12.3. Market Value Forecast, by Treatment, 2017-2031
- 12.3.1. Surgery
- 12.3.2. Radiation Therapy
- 12.3.3. Chemotherapy
- 12.3.4. Targeted Drug Therapy
- 12.3.5. Others
- 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Rest of Latin America
- 12.5. Market Attractiveness Analysis
- 12.5.1. By Type
- 12.5.2. By Treatment
- 12.5.3. By Country/Sub-region
13. Middle East & Africa Glioma Treatment Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Type, 2017-2031
- 13.2.1. Low-Grade
- 13.2.1.1. grade I
- 13.2.1.2. grade II
- 13.2.2. High-grade
- 13.2.2.1. grade III
- 13.2.2.2. grade IV
- 13.3. Market Value Forecast, by Treatment, 2017-2031
- 13.3.1. Surgery
- 13.3.2. Radiation Therapy
- 13.3.3. Chemotherapy
- 13.3.4. Targeted Drug Therapy
- 13.3.5. Others
- 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.4.1. GCC Countries
- 13.4.2. South Africa
- 13.4.3. Rest of Middle East & Africa
- 13.5. Market Attractiveness Analysis
- 13.5.1. By Type
- 13.5.2. By Treatment
- 13.5.3. By Country/Sub-region
14. Competition Landscape
- 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
- 14.2. Market Share Analysis By Company (2021)
- 14.3. Company Profiles
- 14.3.1. Bristol-Myers Squibb Company
- 14.3.1.1. Company Overview
- 14.3.1.2. Company Financials
- 14.3.1.3. Growth Strategies
- 14.3.1.4. SWOT Analysis
- 14.3.2. Genentech, Inc. (F. Hoffmann-La Roche Ltd.
- 14.3.2.1. Company Overview
- 14.3.2.2. Company Financials
- 14.3.2.3. Growth Strategies
- 14.3.2.4. SWOT Analysis
- 14.3.3. Pfizer, Inc.
- 14.3.3.1. Company Overview
- 14.3.3.2. Company Financials
- 14.3.3.3. Growth Strategies
- 14.3.3.4. SWOT Analysis
- 14.3.4. Merck & Co., Inc
- 14.3.4.1. Company Overview
- 14.3.4.2. Company Financials
- 14.3.4.3. Growth Strategies
- 14.3.4.4. SWOT Analysis
- 14.3.5. Teva Pharmaceutical Industries Ltd
- 14.3.5.1. Company Overview
- 14.3.5.2. Company Financials
- 14.3.5.3. Growth Strategies
- 14.3.5.4. SWOT Analysis
- 14.3.6. Sun Pharmaceutical Industries Ltd.
- 14.3.6.1. Company Overview
- 14.3.6.2. Company Financials
- 14.3.6.3. Growth Strategies
- 14.3.6.4. SWOT Analysis
- 14.3.7. Amgen, Inc.
- 14.3.7.1. Company Overview
- 14.3.7.2. Company Financials
- 14.3.7.3. Growth Strategies
- 14.3.7.4. SWOT Analysis
- 14.3.8. Other prominent players
- 14.3.8.1. Company Overview
- 14.3.8.2. Company Financials
- 14.3.8.3. Growth Strategies
- 14.3.8.4. SWOT Analysis